Trial reportDrug design, development and therapy2026
Oliceridine versus Sufentanil for Postoperative Recovery and Opioid-Related Adverse Events in Patients Undergoing Thoracoscopic Lobectomy: A Randomized Double-Blind Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Oliceridine used for patient-controlled analgesia on postoperative quality of recovery in patients undergoing laparoscopic gynecological tumour resection: a randomized clinical trial.Annals of medicine · 2026Trial
- Comparison of Oliceridine and Hydromorphone for Postoperative Analgesia in Adults Undergoing Lower Limb Fracture Surgery: A Randomized Controlled Non-Inferiority Trial.Drug design, development and therapy · 2026Trial
- Beyond Opioid Comparison: Interpreting Oliceridine in Contemporary Thoracic Recovery Pathways [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the efficacy and safety of oliceridine for anesthesia induction, maintenance and analgesia in patients undergoing thoracoscopic lobectomy. Patients and Methods: In this single-center, prospective, double-blind, randomized controlled trial, patients scheduled for surgery between October 2024 and August 2025 were divided into two groups: oliceridine group (Group O) and sufentanil group (Group S). Study drugs were used for anesthesia induction, maintenance and postoperative analgesia. The primary outcome was the incidence of postoperative opioid-related adverse events within the first 48 hours, including PONV, respiratory depression, dizziness, pruritus, and constipation. Secondary outcomes included hemodynamic parameters, NRS and Ramsay Sedation Scale at multiple time points of post-surgery (2h, 6h, 12h, 24h, and 48h), the usage of postoperative analgesia drugs, rescue treatments, and Quality of Recovery-15 (QoR-15) scores. Results: A total of 166 patients were enrolled (Group O: n=83, Group S: n=83). Compared to Group S, Group O showed significantly lower rates of PONV and respiratory depression (P<0.05) and higher QoR-15 scores at 24h and 48h (P<0.05). No significant differences were found in hemodynamics, NRS scores, or Ramsay scores between the two groups (P > 0.05). Conclusion: Oliceridine provides safe and effective perioperative analgesia for patients undergoing thoracoscopic lobectomy. It maintains stable hemodynamics, achieves analgesic efficacy comparable to sufentanil, and demonstrates a superior profile in reducing opioid-related adverse events while promoting postoperative recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.